FDA says the risk will be noted in a labeling change for bisphosphonate medications that treat osteoporosis and in a medication guide for each patient. FDA is still unclear about whether bisphosponates are the cause of the bone breaks.
The agency will continue to evaluate bisphosponates for osteoporosis treatment.
Read the FDA report on bisphosphonates.
Read other coverage on FDA decisions:
– FDA to Revoke OK of Menaflex Knee Implant, Citing Meddling by Congressmen, Former FDA Commissioner
– 32 Orthopedic and Spine Devices Receive FDA Clearance in August
– FDA Sends Johnson & Johnson Letter of Warning
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
